Mike Heffernan | CEO |
Paul Brannelly | CFO |
Joe Ciaffoni | COO |
David Amsellem | Piper Jaffray |
Ken Trbovich | Janney Montgomery Scott |
Serge Belanger | Needham & Company |
David Steinberg | Jefferies |
Kevin Kedra | Gabelli & Company |
Ashiq Mubarack | William Blair |
Welcome to the Collegium Pharmaceutical's Third Quarter 2017 Earnings Conference Call.
Before we begin today's call, we wish to inform participants that the forward-looking statements made today are pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation the risk that we will not be able to successfully commercialize Xtampza. Furthermore, we are subject to patent infringement litigation and may in the future be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay commercialization. These risks and other risks of the Company are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.